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Abstract
The medicinal properties of Manuka honey have been extensively studied, particularly in
terms of its wound healing and antimicrobial activities. We have previously demonstrated
that Manuka honey also has anti-cancer properties against a variety of cancer cell types in
vitro as well as in preclinical cancer models. The cellular targets of the anti-cancer activity of
Manuka honey, however, remain unknown. For the present study, we selected the triplenegative human breast cancer cell line, MDA-MB-231, to investigate susceptibility to
Manuka honey and to identify the potential signaling pathways affected. MDA-MB-231
cancer cells are known to constitutively express activated STAT3 transcription factor. This is
due to mutations in upstream tyrosine kinases that effectively maintain STAT3 in a
phosphorylated, and thus activated, form. These cells are also known to secret IL-6
constitutively, thus creating a positive feedback loop that drives their proliferation and
survival. Our findings demonstrate that treatment with Manuka honey led to inhibition of
STAT3 tyrosine phosphorylation in a concentration and time-dependent manner. Inhibition
of STAT3 activity was observed as early as 15 minutes after cell co-culture with as little as
1% solution of Manuka honey. Importantly, treatment with Manuka honey also led to
decreased IL-6 production. As a consequence, we observed a reduction in the level of antiapoptotic protein Bcl-2 and an increased in the protein expression of cytochrome c,
ultimately leading to the death of cancer cells. Heat-treatment of Manuka honey abolished its
effect on STAT3 phosphorylation and cytocidal capacity. In conclusion, our findings identify
novel targets affected by treatment with Manuka honey in triple negative human breast
cancer cells. The influence of the blockade of this pathway by Manuka honey on other types
of human cancers remains to be investigated.

Keywords: Manuka honey, cancer, STAT3, IL-6, Triple negative breast cancer.
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)Title and Abstract (in Arabic

اﻻھﺪاف اﻟﺠﺰﯾﺌﯿﺔ ﻟﻌﺴﻞ اﻟﻤﺎﻧﻮﻛﺎ ﻓﻲ ﺳﺮطﺎن اﻟﺜﺪي اﻟﺒﺸﺮي
اﻟﻣﻠﺧص

ﻋﺴﻞ اﻟﻤﺎﻧﻮﻛﺎ ﻟﮫ ﺧﺼﺎﺋﺺ طﺒﯿﺔ ﻛﺜﯿﺮة ﻣﻨﮭﺎ اﻟﻤﺴﺎﻋﺪة ﻋﻠﻰ اﻟﺘﺌﺎم اﻟﺠﺮوح و ﻛﻤﻀﺎد
ﺣﯿﻮي و ﻗﺪ اﺛﺒﺘﻨﺎ ﻓﻲ دراﺳﺔ ﺳﺎﺑﻘﺔ أن ﻟﮫ ﻗﺪرة ﻋﻠﻰ ﻗﺘﻞ اﻟﺨﻼﯾﺎ اﻟﺴﺮطﺎﻧﯿﺔ .اﻟﮭﺪف ﻣﻦ اﻟﺪراﺳﺔ
اﻟﺤﺎﻟﯿﺔ ھﻮ ﺗﺤﺪﯾﺪ ﺗﺄﺛﯿﺮ ﻋﺴﻞ اﻟﻤﺎﻧﻮﻛﺎ ﻋﻠﻰ اﻹﺷﺎرات اﻟﺨﻠﻮﯾﺔ ﻓﻲ ﺧﻼﯾﺎ ﺛﺪي ﺳﺮطﺎﻧﯿﺔ ﺗﻌﺮف
ﺑﺎﺳﻢ  . MDA-MB-231ھﺬه اﻟﺨﻼﯾﺎ ﺗﻌﺮف ﺑﺄن  STAT3ﻣﺘﻮﻓﺮ ﻓﻲ ﺣﺎﻟﺔ ﻧﺸﻄﺔ ﻧﺘﯿﺠﺔ
طﻔﺮات ﻓﻲ اﻟﺘﺎﯾﺮوزﯾﻦ ﻛﺎﯾﻨﺎز اﻟﺬي ﯾﺒﻘﻲ  STAT3ﻣﻔﺴﻔﺮ )أي ﻧﺸﻂ( ،ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ أن ھﺬه
اﻟﺨﻼﯾﺎ ﺗﻔﺮز  IL-6اﻟﺬي ﯾﺤﻔﺰ ﻋﻤﻠﯿﺎت اﻟﺘﻜﺎﺛﺮ و اﻟﺒﻘﺎء .ﻧﺘﺎﺋﺞ اﻟﺪراﺳﺔ أﺛﺒﺘﺖ أن ﻋﺴﻞ اﻟﻤﺎﻧﻮﻛﺎ
ﯾﺜﺒﻂ ﻓﺴﻔﺮة  STAT3ﻓﻲ ﺧﻼل  15دﻗﯿﻘﺔ و ﺑﺎﺳﺘﺨﺪام ﺗﺮﻛﯿﺰ ﻣﻨﺨﺾ ﻣﻦ اﻟﻌﺴﻞ ) (%1و ھﺬا
اﻟﺘﺄﺛﯿﺮ ﯾﺘﺰاﯾﺪ ﺑﺰﯾﺎدة وﻗﺖ اﻟﺘﻌﺮض و اﻟﺘﺮﻛﯿﺰ اﻟﻤﺴﺘﺨﺪم .ﺑﻺﺿﺎﻓﺔ إﻟﻰ ذﻟﻚ ﻋﺴﻞ اﻟﻤﺎﻧﻮﻛﺎ ﻗﺎم
ﺑﺨﻔﺾ ﻣﺴﺘﻮى  .IL-6ﻧﺘﯿﺠﺔ ﻟﮭﺬه اﻟﺘﻐﯿﯿﺮات ﻻﺣﻈﻨﺎ ھﺒﻮطﺎ ﻓﻲ ﻣﺴﺘﻮى ﺑﻌﺾ اﻟﺒﺮوﺗﯿﻨﺎت
اﻟﻤﺴﺆوﻟﺔ ﻋﻦ ﻣﻨﻊ ﻣﻮت اﻟﺨﻼﯾﺎ اﻟﻤﺒﺮﻣﺞ ) (Bcl-2و زﯾﺎدة ﻓﻲ اﻟﺴﯿﺘﻮﻛﺮوم ﺳﻲ
) (cytochrome-cﻣﺆدﯾﺔ إﻟﻰ ﺗﺤﻔﯿﺮ ﻣﻮت اﻟﺨﻼﯾﺎ اﻟﺴﺮطﺎﻧﯿﺔ .ﻟﻮﺣﻆ أن ھﺬه اﻟﻘﺪرات ﺗﻔﻘﺪ
ﻋﻨﺪﻣﺎ ﯾﺘﻌﺮض اﻟﻌﺴﻞ ﻟﻠﺤﺮارة اﻟﻌﺎﻟﯿﺔ .ﻓﻲ اﻟﺨﺘﺎم ،ھﺬه اﻟﺪراﺳﺔ ﺑﯿﻨﺖ أھﺪاﻓﺎ ﺧﻠﻮﯾﺔ ﻣﮭﻤﺔ ﻟﻌﺴﻞ
اﻟﻤﺎﻧﻮﻛﺎ ﻓﻲ ﺧﻼﯾﺎ ﺳﺮطﺎن اﻟﺜﺪي و ﻣﺰﯾﺪ ﻣﻦ اﻷﺑﺤﺎث ﻣﻄﻠﻮﺑﺔ ﻟﺘﺤﺪﯾﺪ ﺗﺄﺛﯿﺮ ﻋﺴﻞ اﻟﻤﺎﻧﻮﻛﺎ ﻋﻠﻰ
ﺧﻼﯾﺎ ﺳﺮطﻨﯿﺔ أﺧﺮى.
ﻣﻔﺎھﯿﻢ اﻟﺒﺤﺚ اﻟﺮﺋﯿﺴﯿﺔ :ﻋﺴﻞ اﻟﻤﺎﻧﻮﻛﺎ ،اﻟﺴﺮطﺎن ،ﺳﺮطﺎن اﻟﺜﺪي  ،ﻣﻮت اﻟﺨﻼﯾﺎ.
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Chapter 1: Introduction
1.1 Cancer: background
Cancer is defined as multistep process that starts with a genetic mutation
interfering with cellular signaling circuitry, causing the cell to acquire traits that
sustain cellular immortality, enabling survival signals, chronic proliferation and
ultimately leading to invasion and metastasis (Figure 1) [1]. This leads to the
modification of the tumor microenvironment that favors tumor growth and selfsufficiency. The dysregulation of the endogenous genes results in the activation of
many silenced genes, manipulation of the molecular regulatory mechanisms,
overexpression of growth signals and biased imbalance between pro-apoptotic and
anti-apoptotic proteins [1].

Figure 1: Acquired functional capabilities of cancer cells. Accessed on 30
October 2015, from http://myelomacinderella.net/2015/03/cancer-hallmarkssignalling-pathways-mm-drugs/cancer-functional-pathways-lg/.
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Cancer is known to behave like “unhealed wound” characterized by heavily
infiltrated immune cells creating inflammatory environment surrounding the tumor
niche.

This provides molecules, such as growth and survival factors, and

extracellular-matrix modifying enzymes that foster tumor progression, invasion,
metastasis and angiogenesis [1]. Collectively, therefore, the tumor microenvironment
plays a critical role in supporting the survival and growth of malignant cells.
The tissue microenvironment is an important player that shifts the homeostasis
balance, creating a favorable niche for a precancerous cell to become malignant. The
transition from a normal cell to a malignant one involves two processes: initiation
(one or more genetic mutations) and tumor promotion [2]. Numerous elegant studies
have been published in support of this concept. In an early study carried out by
David Dolberg and Mina Bissell, Rouse sarcoma virus (RSV), a virus that causes
sarcoma in chickens, was injected into the wings of early embryos [3]. They found
that these embryos grew normally even in the existence of an active src oncogene, a
proto-oncogene that encodes a non-receptor tyrosine kinase protein [3]. What is more
interesting is that when they removed the wings and the cells cultured for 24 hours,
these cells that were infected with src oncogene become, transformed [3]. This
clearly supports the notion that, the embryonic unique microenvironment inhibited
the ability of vigorous oncogene such as src to cause sarcoma. Therefore, the tissue
environment has an influential effect on malignant cells. Even in the presence of
malignant cells, the microenvironment is able to constrain tumor growth hence, any
alteration can change the inhibitor into a promoter of tumor growth.
The immune system has also been shown to play an important role in cancer
progression. Based on autopsy studies, individuals who died from trauma were often
found to have microscopic clusters of cancer cells, known as “in situ” carcinoma [4].
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In a 1934 study conducted on autopsies, of 292 male aged 50 years or more, who
died from cancer-unrelated causes, 41 cases were found to harbor prostate carcinoma
lesions, some a few millimeters in size, in their prostate gland [5]. Therefore, it is
not unusual to develop cancerous lesions that may or may not advance to clinically
diagnosed cancer. This is due to the immunosurveillance mechanisms that keep the
growth of cancer cells under control [6]. Hence, successful growth of cancers occurs
at the expense of a compromised immune system.
Collectively, therefore, genetic instability, host’s immune system and tumor
microenvironment play crucial roles in cancer initiation and progression. Our
enhanced understanding of these factors will aid in the development of effective
therapeutic anticancer strategies.
1.2 Current Conventional Cancer Treatment
Over the past 50 years, cancer therapeutic strategies have focused on three
main treatment modalities: surgery, radiation and cytotoxic drugs. More recently,
targeted based therapy and immunotherapy have become increasingly used as
treatment options. These various modalities are used in combination to ensure the
eradication of the cancerous tissue/cells [7].
Surgery is one of the oldest approaches used against cancer. It is defined as a
procedure used to remove or restore the diseased or injured portion of the body [8].
Surgery is useful as long as the tumor cells are confined and localized for easy
removal. Therefore, it is considered as a possible curative method and doesn’t protect
against cancer reoccurrence.

4

On the other hand, radiation is a therapy that uses beam of X-rays to cause extensive
DNA damage in the tumor cells through the generation of free radicals, this damage
can’t be repaired and thus leads to cell death [9]. Since the efficacy of radiotherapy
depends on the generation of free radical species from oxygen, the hypoxic
conditions within the tumor tissue act to limit the effectiveness of radiation [10].
Maintaining the tumor’s inner tissue in a hypoxic state allows the cancer cells to
resist killing by radiotherapy. Even though this therapy is considered localized, both
short and long-term complications are associated with radiotherapy. In the shortterm, cytotoxicity on highly proliferating cells, such as skin, hair, bone marrow and
gastrointestinal

track,

causing

vomiting,

nausea,

diarrhea,

and

severe

immunosuppression [10]. Moreover, long-term effects of radiation include increased
potential for the development of secondary cancer, infertility, joint problems and
lymphedema [10].
Conventional chemotherapeutic agents target cancer cells and trigger their death
through interfering with essential cellular processes [9]. Although rapid proliferation
is a hallmark of cancer, the body also contains normal cells that tend to divide
rapidly. For example cells of the bone marrow, oral cavity and mucosal lining of
intestine, hair follicles, ova and sperms. Cancer complexity is as Walt Kelly, an
American animator, quotes “We have met the enemy, and he is us”; cancer cell is
much like a normal cell, but with abnormal properties [11]. Unfortunately, current
chemotherapy regimens don’t distinguish between normal and cancerous cells, hence
their systemic effect. Notwithstanding their toxicity, chemotherapeutic drugs have
had an enormous impact judging by the improved overall survival rates observed in
cancer patients, especially in Hodgkin's disease, acute lymphocytic leukemia of
childhood, choriocarcinoma and Burkitt's lymphoma [12]. The lack of specificity
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remains a serious concern and creates a major challenge for limiting the harmful
effects on normal cells. The consequences of chemotherapy are sufficiently serious
for many to express the need for “Treating the Treatment” [13]. These toxicities
often occur at the level of the therapeutic dose and thus are unavoidable [13]. In
addition, the combination treatment regimens are also a main cause of
chemotherapy-associated toxicities. Because of the similarities in the side effects
caused by many chemotherapy drugs, combination drug regimens often lead to
additive toxicities, such as nephrotoxicity, cardiomyopathy, pulmonary damage and
sterility [12, [14]. Psychiatric consequences, including depression, have been
reported among breast cancer survivors as a complication of chemotherapy [15].
Given that some chemotherapeutic drugs are carcinogenic in nature, particularly
alkylating agents such as cisplatin, the development of secondary malignances
remains a serious long-term side effect [16, 17] . Because chemotherapeutic drugs
often target cancer cells, they do not actively utilize the patient’s immune system in
their eradication. One of the well-recognized consequences of chemotherapy is bone
marrow suppression, which results in neutropenia and lymphopenia among other
effects. In this way, chemotherapeutic drugs can be thought of as acting against the
body’s anti-tumor immune defense systems, thereby contributing to another layer of
potentially deleterious complication. The failure to harness the immune system in the
fight against cancer cells along with chemotherapy is a major hurdle with the
currently used therapeutics toward a complete cure without recurrences. The ideal
cancer treatment should not only focus on killing cancer cells but, rather, it should
employ the body’s defense mechanisms to achieve a durable disease-free survival
[18]. It is generally believed that tumor cells arise spontaneously and continuously
throughout one’s life span. For the major part, a healthy immune system can
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recognize and eliminate, or at least control, these mutated cells effectively [19].
Development of symptomatic cancer is inherently linked to either a failure in the
immune surveillance system or to the ability of cancer cells to develop mechanisms
that effectively help in evading anti-tumor immune responses. The recent astounding
successes reported in clinical trials using newly developed immunotherapeutic drugs
are a testament to the critical role of the immune system in fighting cancer [20-22].
Finally, to overcome current conventional treatment obstacles, a multidimensional
treatment strategy that addresses the whole body is needed, one that efficiently
destroys cancer cells while maintaining the patient’s strength and vitality.
1.3 Natural Therapies in Cancer Treatments
Despite the remarkable breakthroughs in cancer research, tumor resistance,
recurrence and toxicities associated with current standard therapies are considered
major challenges facing cancer treatment. This may explains the overall modest
improvement in cancer death rate since 1950 [23]. Over the past 75 years, cancer was
the second leading cause of death in the USA [24]. Worldwide, about 14.1 million
new cases and about 8.2 million death occurred in 2012 [25]. This clearly indicates
the failure of the current conventional treatments to eradicate cancer.
Given the above facts, screening for new anti-cancer agents with novel properties
becomes a real necessity. Ideally, anti-tumor compounds that have the capacity to
limit cancer resistance, reduce drug-associated toxicities, or enhance the safety
profile and efficacy of current chemotherapeutic drugs are required. Recognizing that
Nature is the perfect reservoir for drug discovery, the National Cancer Institute (NCI)
announced a large-scale screening of natural compounds that possess anticancer
activity in 1960 [26]. Natural compounds can be found in marine life forms,
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microorganisms, plants or in dietary agents [27]. Key factors underlying the potency
of natural products include chemical diversity, structural resemblance of protein
targets throughout many species [28, 29]. The bioactive compounds are usually
tested either as crude form or as pre-fractionated extracts [28]. Remarkably, many of
these novel compounds were reported to exhibit various biological effects, for
example antimicrobial or anti-proliferative activities, on different types of cancer
[30]. Nature has been an inspiring and continuous source for many novel drug
discoveries but many more compounds a wait to be discovered.
1.4 Honey: An ancient therapy
One of nature’s potent drugs is honey, a natural substance formed from the
nectar and the secretion of plants by the honeybees, Apis mellifera [31]. After the
intake of the nectar, the bees add a particular enzyme made in their body that
converts the nectar into honey [32]. Different types of honey are made depending on
the nectar source (plants). Honey was known as a traditional medicine for as far
back as 4000 years ago [33]. The ancient Egyptians, Chinese, Greeks and the
Romans described the use of honey in wound healing and in the treatment of gut
diseases [34]. Hipprocrates recommended the intake of honey to preserve health and
physical strength [35]. Also, the Nobel Quran, religious text of Islam, emphasizes the
potential benefits of honey and bees thus “And your Lord inspired to the bee, Take
for yourself among the mountains, houses, and among the trees and [in] that which
they construct. Then eat from all the fruits and follow the ways of your Lord laid
down [for you]. There emerges from their bellies a drink, varying in colors, in which
there is healing for people, indeed in that is a sign for a people who give thought”
(Surat Al-Nahl “The Bees”, Aya 69).
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Nowadays, modern science proves and confirms what has been known several
thousands of years ago, the medicinal properties of honey. The therapeutic potential
of honey is attributed mainly to its wound healing properties. However, current
evidence indicates that honey has a broad spectrum of actions. In fact, it contains
compounds that act as antioxidant, anti-inflammatory, antibacterial and anticancer.
Honey medicinal properties and cancer pathological behavior revealed an inverse
relationship that Dr. Nor explained in her review [36], summarized in Figure 2.
Evidence-Based Complementary and Alternative Medicine

Has high antioxidant
Is a scavenging agent for toxic free radicals

Honey

Is natural antimicrobials

Causes of cancer
Accumulation of toxic free radicals reactive
oxygen species due to
• Smoking
• Alcohol
• Obesity
• Chronic infections, etc.
Chronic infections, e.g., bacteria (H. pylori),
virus (HPV, EBV, Hep. B, C), parasites
(schistosomiasis), fungus (Aspergillus flavus)

Is natural immune booster

Low immune status, e.g., due to diabetes,
chronic illness, obesity

Is natural anti-inflammatory agent

Chronic inflammation, e.g., colorectal carcinoma in
Crohn’s disease and ulcerative colitis

Is “fixer” for chronic ulcers and wounds

Chronic nonhealing ulcers, e.g., squamous cell
carcinoma developing in chronic traumatic
wounds

Has potential as cancer therapeutic agent

Genetic inheritance

Cancer

Properties of honey

5

Cause unknown

Figure 4: The inverse relationship of honey and cancer.

Figure 2: The inverse relationship of honey and the cancer. Obtained from: Nor Hayati
Othman, Honey and Cancer: Sustainable Inverse Relationship Particularly for
response, the body defense mechanisms in trying to rid
6. Honey As Natural Antimicrobials
Developing
Nations—A
Review,
Evidence-Based
Complementary and Alternative
of the
irritants. In general
inflammatory
responses
are
Everyday we are exposed to all kinds of microbial insults
beneficial
and
protective
to
us,
but
at
times,
inflammatory
Medicine, vol. 2012, 10 pages, 2012.
from bacteria, viruses, parasites, and fungi. Honey is a

responses are detrimental to health. Honey is a potent antiinflammatory agent. Infants suﬀering from diaper dermatitis
improved significantly after topical application of a mixture
containing honey, olive oil, and beeswax after 7 days [68].
Honey provides significant symptom relief of cough in
children with an upper respiratory tract infection (URTI)
[69]. It has been shown to be eﬀective in management
of dermatitis and Psoriasis vulgaris [70]. Eight out of 10
patients with dermatitis and five of eight patients with
psoriasis showed significant improvement after 2 weeks on
honey-based ointment [70]. Honey at dilutions of up to
1 : 8 reduced bacterial adherence from 25.6 ± 6.5 (control)
to 6.7 ± 3.3 bacteria per epithelial cell (P < 0.001) in
vitro [71]. Volunteers who chewed “honey leather” showed
that there were statistically highly significant reductions in
mean plaque scores (0.99 reduced to 0.65; P = 0.001)
in the manuka honey group compared to the control
group suggesting a potential therapeutic role for honey for

potent natural antimicrobial. The most common infections
humans get are from staphylococcal infection. Antibacterial
eﬀect of honey is extensively studied. The bactericidal
mechanism is through disturbance in cell division machinery
[75]. The minimum inhibitory concentration (MIC) for
Staphylococcus aureus by A. mellifera honey ranged from
126.23 to 185.70 mgml−1 [76]. Honey is also eﬀective against
coagulase-negative staphylococci [77]. Local application of
raw honey on infected wounds reduced signs of acute
inflammation [78], thus alleviating symptoms. Antimicrobial activity of honey is stronger in acidic media than in
neutral or alkaline media [78]. The potency of honey is
comparable to some local antibiotics. Honey application
into infective conjunctivitis reduced redness, swelling, pus
discharge, and time for eradication of bacterial infections
[78]. When honey is used together with antibiotics, gen-
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Honey, as Dr.Nor described, can be called as “Natural cancer vaccine”, due to its
several bioactivities. It reduces the chronic inflammation, a pathological risk of
cancer development [36]. It also boosts the immune system, since cancer is caused
due to failure in the immunosurveillance system [36].
According to Fukuda et.al [37], Jungle honey (JH), a honey from the forest area in
Nigeria, contains chemotactic activity for neutrophils. More importantly, when mice
with Lewis lung carcinoma/2 (LL/2) treated i.p with JH (1 mg/mouse/day). It was
found that frequency and mean weight of LL/2 tumors were reduced [37]. Histology
revealed a massive neutrophil infiltration in the tumor tissue, hence they suggested
that the reduce tumor burden was due to the neutrophils inhibiting the tumor growth
[37].
Furthermore, it has been shown by many researchers [36, 38, 39] that honeys from
different geographical and climatic zones and floral sources, can induce apoptosis in
various cancer cells types. Honey is effective in killing cancer cells, because it
contains several kinds of phytochemicals (phenolic and flavonoid compounds),
which explains its high anti-inflammatory and antioxidant activity [36]. Yaacob and
colleagues investigated the anticancer effect of Tualang honey, wild rainforest honey
from Malaysia. They found that this honey exhibit cytotoxic potential against human
breast adenocarcinoma (MCF-7 and MDA-MB-231) and in human cervical
carcinoma (Hela) [40]. They observed a depolarization of the mitochondrial
membrane potential that leads to the induction of apoptosis, an ideal way of death
[40]. Jubri et al. demonstrated the anti-proliferative activity of Gelam honey, a
monofloral honey from Malaysia, against human liver carcinoma cells (HepG2),
which is due to the induction of apoptosis [41]. On the other hand, it did not have an
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affect on normal liver cells viability (WRL-68), which indicates a selective
cytotoxicity against liver cancer cells [41].
Notably, the honey is considered as chemopreventive agent, nature substances that
reverse, suppress, or prevent the development of cancer [42]. A study done by
Oršolić et al. revealed the pronounced anti-metastatic properties of the honey, when
mice received honey orally (2g/kg/day) for 10 consecutive days before tumor cell
inoculation in the lung [43]. Interestingly, Mabrouk and colleagues showed the
protective effect of honey and Nigella grains against provoked carcinogenesis by
methylnitrosourea (MNU), a chemical that is classified as human carcinogen, in
Sprague Dawely rats [44]. This protection reached 100% of rats and there was no
evidence of an increase in the malondialdehyde (MDA) nor the nitric oxide (NO) in
the sera of these animals, both indicators of MNU-induced oxidative stress [44].
Honey is a potent antioxidant and scavenger of toxic free radicals, thus preventing
DNA damage to the cells [36, 38, 39]. Blasa et al. investigated the effect of Italian
honey flavonoid as antioxidant agent; they showed that honey flavonoid prevents
oxidative damage against human red blood cells [45].
In addition to the above mentioned honey properties, the honey contains numerous
kinds of phytochemicals that varied in concentration and availability. Recently, many
researchers

become

interested

in

studying

the

anticancer

activities

of

phytochemicals. Phytochemicals are chemicals compounds created by the plants and
present in the honey that gives a distinctive flavor, smell, and color. Polyphenols can
be narrowed down to flavonoids and phenolic acids. Extensive research has shown
the therapeutic properties of those polyphenols. For example, caffeic acid pheneyl
ester (CAPE), a natural phenolic compound found in honey and propolis extract, was
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shown by Maruta et.al [46] to inhibit vital signaling pathways in cancer growth,
proliferation and survival. It was found that CAPE blocked completely the growth of
the human cancer Neurofibromatosis (NF1), a type of cancer that is found in the
protective lining of the nerves that extend from the spinal cord into the body [47].
Moreover, CAPE was found to inhibit specifically nuclear factor-kappa-B (NFκΒ), a
transcription factor that can induce the expression of multiple target genes important
for cell proliferation, survival, metastasis and angiogenesis [30].
Krol et.al investigated the cytotoxic effect of propolis extract (EEP) and thirteen
other phenolic compounds on the human cervical cancer cell line, HeLA [48]. When
EEP was added together with TRAIL (tumor necrosis related apoptosis inducing
ligand), a protein that binds to the death receptor and programmed cell death, it was
found that HeLA cells, a TRAIL-resistant cell line, was significantly sensitized to
TRAIL mediated apoptosis [48]. This clearly indicated the EEP could work
synergistically in combination TRAIL and overcomes cancer cell resistant to
extrinsic programmed cell death. These scientific findings seem to prove the
efficiency of different honey types against several forms of cancer, both in cell
cultures and animal models. The honey properties strongly support the therapeutic
potential use of honey in cancer therapy. A further in-depth investigation is needed to
uncover underlying mechanism/s of honey as a cancer treatment. In summary, cancer
should be attacked at different levels rather than one specific angle; thus might
reduced the chance of the cancer become resistant to the current treatment and
recurrences.
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1.5 Manuka Honey
Manuka honey is a monoforal honey in which the bee depends primarily on
one plant to collect the nectar from and hence it is named after this plant [49]. This
honey originates from the Manuka tree, flowering plant called Leptospermum
scoparium, which flourishes as a shrub or a small tree throughout New Zealand and
Eastern Australia (Figure 3) [49]. The native people recognize the Manuka tree as an
“Antibacterial Medicine”.

Figure 3: Manuka tree, Leptospermum scoparium. Accessed on 11
October 2015, from http://www.soulsister.co.za/wp/2013/08/manuka/.

The chemical composition of the Manuka honey consists of: sugar mainly fructose
and glucose about 95%; enzymes such as invertase (breakdown sucrose), glucose
oxidase (oxidizes glucose and converts oxygen into hydrogen peroxide) and catalase
(catalyzes the hydrogen peroxide into water and oxygen); amino acids; vitamins;
minerals; flavonoids and phenolic acids [39]. Table 1, below, illustrates in details
about the flavonoids, phenolic acids and other compound found in Manuka honey.
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Table 1: Most common flavonoids, phenolic acids and other compound in Manuka
honey [49]
Flavonoids and
Phenolic Acids

Reference

Other compounds

Reference

Caffeic Acid

[50]

Phenyllactic acid

[39]

Isoferulic Acid

[39]

4-Methoxyphenolactic
Acid

[39]

p-Coumaric Acid

[50]

Kojic Acid

Gallic Acid

[51]

5-Hydroxymethyfurfural

[52]

4-Hydrobenzonic
Acid

[39]

2-Methoxybenzoic Acid

[39]

Syringin Acid

[51]

Phenylacetic Acid

[39]

Quercetin

[50]

Methyl syringate

[39]

Leuteolin

[50]

Dehydrovomifoliol

[39]

8-Methoxykaempferol

[50]

Leptosin

[39]

Pincocembrin

[50]

Gyoxal

[39]

Isorhamnetin

[50]

Methylglyoxal

[52]

kaempferol

[50]

3-Deoxyglucosulose

[39]

Chrysin

[50]

-

-

Galangin

[50]

-

-

Pinobanksin

[50]

-

-
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Manuka honey has been extensively studied due to its various pharmacological
activities in wound healing, fungal/bacterial infections, ophthalmic conditions,,
gastrointestinal diseases and skin ulcers [53]. Dr. Peter Molan discovered the first
notable feature of the Manuka honey: wound healing and antibacterial properties.
Manuka honey pH ranges between 3.2 to 4.5, thus prevents the growth of microbes,
since they like to live at pH 7.2 -7.4 [54]. Additionally, honey osmolality, due to the
high sugar content, draws fluids out of the tissue and leaves the wound area in a
moist environment accelerating the healing processes [54, 55].
Surprisingly, Manuka honey antibacterial potency is extraordinary, because it is the
only honey that can kill bacteria in non-peroxide fashion. Dr.Molan proved this fact
by adding catalase to the honey and measuring bacterial zone of inhibition. The
result was that even in the presence of catalase the Manuka antibacterial activity was
stable [56]. This experiment clearly indicated the presence of other compounds that
act as anti-bactericidal.
Honey is well known as natural immune stimulator. It was reported that Manuka
Honey was able to induce primary human monocytes cells to produce inflammatory
cytokine [57]. Interestingly, they also investigated which components that are present
in Manuka honey are responsible for this induction. They found a heat sensitive 5.8
kDa component different than a Lipopolysaccharide (LPS), since it is heat stable,
was able to immunemodulate and stimulate monocytes, immune cells that circulate
in the blood, to produce inflammatory cytokines via this Toll-like receptor 4 (TLR4)
[57]. Moreover, a study done in rats by Medhi and colleagues, found that oral
administration of Manuka honey (5g/Kg and 10g/Kg) was able to reduced the
colonic inflammation in the experimentally induced inflammatory bowl disease
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compared to untreated rats [58]. The authors explained this protection through lipid
restoration and antioxidant parameters improvement [58].
1.6 Triple Negative Breast Cancer (TNBC)
Breast cancer is the second most common type of cancer diagnosed in woman
and considered as major cause of death in woman [25]. According to the World
Cancer Research in 2012, around 1.7 million new cases of breast cancer worldwide
were diagnosed [25]. In the clinic, breast cancer is classified molecularly into
different subgroup depend on the expression of estrogen receptor (ER), progesterone
receptor (PG) and the overexpression of human epidermal growth factor receptor 2
(Her-2/Neu) [59]. On the other hand, tumors that do not express any of the abovementioned markers are called triple negative breast cancer (TNBC) [60]. In the latter
subgroup, patients tend to have poor prognosis, can’t be treated with Her-2 targeted
therapies nor hormonal therapy and have high recurrence rate [60]. Out of all breast
cancer subtypes, 10-15% approximately accounts for TNBC [59]. They have
mesenchymal-like features and express epidermal growth factor receptor [60].
TNBCs are considered aggressive and difficult to treat (depend on stage at time of
diagnosis), they are frequently chemotherapy-resistant, with p53 mutation and more
importantly have up-regulation of IL-6 and STAT3 [61]. Due to the lack of targeted
therapy, understanding the molecular cell biology of the TNBC may aid to identify
new targets for drug discovery.
STAT3 is persistently activated by tyrosine phosphorylation in about 50% of the
primary breast carcinoma [62]. Constitutive activated STAT3 is not only seen in
breast cancer but also found in head and neck, melanoma, multiple myeloma, ovarian
cancer, adult acute myeloid leukemia, lung cancer, prostate cancer and glioblastoma
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[63-65]. In TNBC specifically, tyrosine phosphorylated STAT3 is constitutively
activated in both tumor derived-cell lines and human specimens [61, 66]. Several
studies showed that STAT3 activation resulted on TNBC progression; hence STAT3
is a possible promising therapeutic target [62, 67, 68].
1.7 Signal Transducer and Activator of Transcription 3 (STAT3) Signaling
Pathway
STAT3 is a latent cytoplasmic protein that functions as secondary messenger
and as a transcription factor. It belongs to a family comprise of seven different Stat
proteins: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6 [69] . All
STAT protein share the same structural features and mechanisms of activation [64].
They usually consist of ~850 amino acids long for STAT2 and 6, and about 750 to
795 amino acid long for STAT 1,2,3,4, 5a and 5b (Fig.4) [70]. The DNA binding
region in the STAT molecules controls the specificity of binding and because this
region is conserved among the STAT proteins, they bind to the same DNA sequence.
Transcription activation domain (TAD) located in the C-terminal of the STAT
proteins is required for the activation of target gene transcription.
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The activation of STAT proteins under normal condition is dependent on cytokine
(such as IFN-α, -β, -γ, IL-2, IL-6 and IL-7) or growth factor (such as EGFR, HER2
and PDGFR) stimulation that binds to the receptor tyrosine kinase (RTK) or cytokine
receptors [70]. Also STAT proteins can be activated through non-receptor tyrosine
kinase such as v-Src or ABL [70].
Following ligand-mediated receptor dimerization, the tyrosine kinase-associated with
the receptor, for example Janus kinase (JAK) or Src, phosphorylates the tyrosine
residue

in

the

cytoplasmic

(transphosphorylation).

tails

of

the

adjacent

receptor

molecule

Thus creates docking site for the recruitment of STAT

molecule (monomeric, non-phosphorylated) via SH2 domain. As a result, STAT
protein becomes tyrosine phosphorylated by the JAK. Phosphorylated STAT
dimerize with other phosphorylated STAT through an interaction between
phosphorylated tyrosine residue in the SH2 domain of each STAT molecule.
Consequently, STAT-STAT dimer translocate to the nucleus, where they bind and
activate transcription of targets genes (figure 5) [69].
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Figure 5: STAT signaling pathway. Obtained from: Buettner et al., Activated
STAT Signaling in Human Tumors Provides Novel Molecular Targets for
Therapeutic Intervention. Clinical Cancer Research, 2002, Vol. 8, #4: 945-954.
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Chapter 2: Summary and Rational
Hypothesis
Given the central role of IL-6/STAT3 signaling pathway in proliferation and survival
of MDA-MB-231 and other human triple negative breast cancers. We hypothesize
that treatment with Manuka honey could block component to this pathway leading to
growth arrest.
Rational
•

Aberrant STAT3 activity is important in cancer development and progression

•

High IL-6 expression and constitutive STAT3 activity have been correlated to
poor prognosis in-patient with advanced breast cancer and resistance to
current chemotherapy treatment.

•

Genes regulated by STAT3 play major role in malignancy through
dysregulation of many important cell-signaling pathways that favor cancer
proliferation, survival, angiogenesis, immune modulation and metastasis.

Objective
The overall objective of this study is to identify proximal targets of the Manuka
honey treatment of cancer cells and to investigate the potential role of Manuka honey
in modulating IL-6/IL-6 receptor/JAK2/STAT3 signaling pathway.
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Chapter 3: Material and Methods
3.1 Summary of materials used suppliers

Materials

Company

BSA

Sigma

10 mm tissue culture treated culture dishes

Corning, NY,USA

96 well tissue culture plates

Corning

6 well tissue culture plates

Corning

NaCl

Sigma

Tris-base

Sigma

Glycine

Sigma

2.2 Western blot Standard solution
1M Tris-CL (pH=7.6): 15.76g Tris-base into 100ml deionized water (dH2O), and
adjust the pH with HCL to “7.6”.
6x sample Buffer (10 ml): 0.375M Tris pH 6.8, 12% SDS, 60% glycerol, 0.6M DTT,
0.06% bromophenol blue.
10x Running Buffer (For 1 Liter): 30g of Tris-base, 140g Glycine, 10g SDS, dissolve
in 1L-dH2O.
10x Transfer Buffer (For 1 Liter): 30g Tris-base, 144g Glycine, dissolve in 1L-dH2O.
10x TBS Buffer (For 1 Liter): 24.2g Tris-base, 80g Nacl, dissolve in 1L-deionized
water (dH2O) and adjust the pH with HCL to “7.6”.
1x T-TBS buffer for 1 liter (membrane washing buffer): 100ml of 10x TBS buffer
with 900ml of dH2O per a liter, then add 0.1% Tween.

21

1.5M Tris-CL buffer for resolving gel (pH 8.8): 18.15g of Tris-base into 70ml
dH2O, adjust the pH with HCL to “8.8” and then make up volume to 100ml.
10% Ammonium persulfate (APS): 1g Ammonium persulfate in 10ml dH2O, store at
-30˚C in 1ml aliquots.

3.3 Antibodies
Antibody

Catalog #

Company

Concentration/dilution
used

Anti-STAT3
Tyr705

9131

Cell Signaling
Technology

1:1000

Anti-STAT3

4904

Cell Signaling
Technology

1:1000

Anti-β actin

4967

Cell Signaling
Technology

1:1000

Anti-IL-6

12153

Cell Signaling
Technology

1:1000

Anti-Bcl2

sc-7382

Santa cruz
Biotechnology

1:1000

Anti-cytochrome c

sc-13561

Santa cruz
Biotechnology

1:500

e-Bioscience

1:1000

Anti-cMyc P68
Anti-NFκB P65

8242

Cell Signaling
Technology

1:1000

Anti-pNFκB P65

3033

Cell Signaling
Technology

1:1000

Anti-SOCS3

2923

Cell Signaling
Technology

1:1000

Anti-phosphoTyrosine

8954

Cell Signaling
Technology

1:1000

(P-Tyr-1000)
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3.4 Cell lines
The triple negative human breast cancer cell line, MDA-MB-231, was
obtained from Prof.Samir Attuib, department of Pharmacology and Therapeutics,
Collage of Medicine and Health Sciences [71]. Tumor cells were maintained in a
complete Dulbecco's modified Eagle's medium (DMEM) containing 5% Fetal
Bovine Serum (FBS) and antibiotics (Penicillin 100U/mL; for Streptomycin
100µg/mL) at 37°C (all reagents from HyClone, GE healthcare Life Sciences, Utah,
USA) [72].
3.5 Western Blot Analysis
MDA-MB-231 cells (4x106 cells/well) were seeded in 100mm x 20mm
culture dish for overnight in 2% FBS DMEM growth medium. The next day 1% and
5% Manuka honey was diluted in 5% DMEM medium and added after the removal
of the previous media. The incubation time of the Manuka treatment started from
0.25, 0.75, 0.5, 1,4,6 and 12 hours. At the end of the incubation period, cells were
harvested, washed and lysed using RIPA buffer (25mM Tris-CL (pH=7.6), 150 mM
sodium chloride (NaCl), 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS), inhibitor cocktail (50mM PMSF, 1M sodium floride, 1M
protease inhibitor and 1M sodium orthovandate). The whole cell lysates were kept on
ice for 30 minutes and vigorously vortex mixed every 15 minutes before
centrifugation at 10,000 rpm for 20 minutes at 4°C to remove insoluble material.
Protein concentration in the samples was determined using Bradford protein assay
(Bio-Rad, California, USA). Afterwards 60-80 µg of total proteins were boiled in 6x
loading buffer (0.375M Tris pH 6.8, 12% SDS, 60% glycerol, 0.6M DTT, 0.06%
bromophenol blue) for 5 minutes. Then separated by SDS polyacrylamide gel (SDA-
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PAGE) and transferred to a nitrocellulose membrane. The membrane was blocked
with 5% non-fat milk for 1 hour and probed with appropriate primary antibodies
overnight at 4°C. The blot was washed 3 times for 5 minutes, and then exposed to
horseradish peroxidase-conjugated secondary antibodies (1:2000, Cell Signaling,
MA, USA) for 1 hour. Protein bands were visualized using the ECL Plus western
Blotting Substrate System (Pierce, Thermo Fisher scientific, MA, USA). The
chemiluminescent band signal was detected by Typhoon FLA 9500 imaging machine
(GE Healthcare Life Sciences, UT, USA). The Densitometric analysis on blots was
quantified using ImageJ (National Institutes of Health, USA).
3.6 IL-6 cytokine western blotting Analysis
MDA-MB-231 cells (4x106 cells/well) were seeded in 100mm x 20mm
culture dish for overnight in 2% FBS DMEM growth medium. The next day 1% and
5% Manuka honey was diluted in 5% DMEM medium and was added after the
removal of the previous media. The total incubation time of the Manuka treatment
was 4.5 hours. The cells were treated with Manuka honey for 0.5 and, then, Brefeldin
A (BFA), fungal metabolite that inhibits protein trafficking from endoplasmic
reticulum to Golgi apparatus (Catalogue# 9972, Cell Signaling Technology, MA,
USA), was added at 1µg/ml concentration for further 4 hours, to trap enough IL-6
cytokine intracellularly to be detect with western blotting. Afterwards protein
extraction and western blot protocol was followed as described above.
3.7 In vitro viability assay
MDA-MB-231 cells were seeded into 96-well plate at 5x103 cells/well in
supplemented 2% FBS DMEM culture medium. Serial dilutions of Manuka (5% and

24

1%) prepared in sterile culture medium were then added to each well.

All

determinations were done in duplicate. After 12, 24 or 48 hr incubation at 37°C, cell
viability was determined using CellTiter- GloH Luminescent cell viability assay
(Promega, Madison, WI, USA). Luminescent signal was measured using GloMax
Luminometer system (Promega, Madison, Wisconsin, USA). Data were presented as
percent cell viability of experimental groups compared with that of the untreated
cells, the viability of which was taken as 100%.
3.8 Reverse Transcription Reaction
RNA was reverse transcribed using TaqMan reverse transcription reagent
(Applied Biosystems #N8080234). Each master mix reaction contained 10x RT
buffer, 25mM MgCl2, deoxy NTPs mixture (2.5mM), random hexamers (50µM),
RNAase inhibitor (20U/µl) and MultiScribe RT enzyme. The master mix was
aliquoted into separate PCR tubes. RNA was added (1µg/10µl per reaction) and total
volume was made up to 50µl with nuclease-free water. The one step RT-PCR
reaction was run on GeneAmp PCR System 2700 from Applied Biosystems, under
the following conditions: hexamer incubation for 10 minutes at 25°C, reverse
transcription at 48°C for 30 minutes and reverse transcriptase inactivation at 95°C for
5 minutes. Samples were held at 4°C for a maximum of 1 hour until they could be
removed and stored at -20°C.
3.9 Real time PCR reactions
The real time PCR was performed using TaqMan gene expression assay as
specified below and amplified using the 7500 Real Time PCR System (Applied
Biosystems). Each 20µl PCR reaction contained 10µl of 2xTaqMan Universal
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Master Mix (Applied Biosystems #4440047), 1µl of 20x TaqMan assay Mix
(Applied Biosystems #4331182), 2µl cDNA and 7µl nuclease free water. A negative
PCR reaction was also carried out using only the reaction mixture without cDNA in
order to ensure that there was no DNA contamination .The thermal cycling
conditions were as follows: 95°C for 10 minutes (inactivation of reverse transcriptase
and activation of TaqMan polymerase), 95°C for 15 seconds (denaturation of
dsDNA) and 60°C for 1 minute (annealing/extension- fluorescent data collected
during this step) for a total of 40 cycles with the threshold set as 0.2. Data was
analyzed using the Ct values for each sample that were in duplicates. Results were
normalized to HPRT (Hypoxanthine-guanine phosphoribosyl transferase) and the
mRNA fold change was determined using the following equation:
Fold change= 2 [

Ct (treated)

]/2[

Ct (control)

], where

Ct(treated) = threshold cycle (Ct)

for target gene after treatment - Ct for HPRT after treatment and Ct(control) = Ct
for target gene untreated - Ct for HPRT untreated. Control used was untreated cells.
The assay ID of the primers used is as follows:
PIAS3 (Hs00966035_m1), PTPN1 (Hs00942477_m1), HPRT (Hs02800695_m1).
3.10 Statistical analysis
Statistical significance was analyzed using Student's t-test using the statistical
program of GraphPad Prism software (San Diego, CA). Differences between
experimental groups were considered significant when p values were <0.05.
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Chapter 4: Results
We previously demonstrated that low concentrations of Manuka honey were
effective in inhibiting the proliferation of several human and murine cancer cell line
(our paper Ref). The cell lines included B16.F1 (a murine melanoma), CT26 (murine
colorectal carcinoma) and MCF-7 (a human mammary carcinoma) [72]. For the
current study, we focused on studying the effect of Manuka treatment on another
human mammary carcinoma (MDA-MB231) that represents a triple-negative variant
lacking in gene expression of estrogen and progesterone receptors and Her2/neu [60].
Triple-negative breast cancer carries the worst prognosis in patients [61].
4.1 Manuka treatment inhibits human breast cancer cell growth
We first investigated the effect of Manuka honey on the viability of MDAMB-231 cells. Accordingly, cells were treated with Manuka honey (at 1% or 5% w/v
final concentration) and incubated for 12, 24 or 48 hours. As shown in Figure 6, the
addition of 1% w/v Manuka honey to cells in culture did not result in any significant
reduction in cell viability (92%, 97% and 88% viability, respectively). On the other
hand, treatment with 5% manuka led to a marked reduction in cell viability, yielding
75%, 59% and 62%, at the different time points, respectively. The inhibitory effect
on cell viability was thus dependent on both honey concentration and total incubation
time.
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Figure 6. Manuka treatment inhibits human breast cancer cell growth. Cells were
plated at 5x10 cells per well and incubated for 12 and 24 or 48 hours in the absence or presence
of the indicated concentrations of manuka honey (1% and 5% w/v). At the end of the incubation
period, cell viability was determined using CellTiter-Glo luminescent assay. Results are expressed
as percentage viability in treated cell cultures compared to control, untreated, cells and are
representative of duplicates wells. Asterisks denote statistically significant differences in viability
of experimental groups compared to control (*, p<0.05).
3

4.2 Manuka treatment inhibits pro-survival protein expression and increase the
cytochrome c protein expression in human breast cancer cell
In the next series of experiments, we addressed the potential mechanism by
which manuka was causing a decrease in cell viability. Accordingly, we investigated
the effect of the treatment on the Bcl-2, anti-apoptotic protein that binds to proapoptotic proteins to inhibit them, and on cytochrome c, a protein located in the
intermembrane space of mitochondria that participate in the activation of apoptosis
upon its release in the cytosol. Therefore, MDA-MB-231 tumor cells were treated
with 1 % or 5% of manuka honey and incubated for different time points ranging
from 15 minutes to 12 hours. The results, shown in Figure 7, reveal significant
decreased level of protein expression in manuka-treated cells compared to untreated
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control. Manuka treatment for 15 minutes reduced Bcl-2 protein level to 68% of
control. A further inhibition of Bcl-2 protein expression is seen after 0.5, 0.75, 1 and
4 hours of Manuka incubation to 22%, 26%, 24% and 21%, respectively. By
contrast, after 6 and 12 hours of treatment the protein level of Bcl-2 starts to recover
slightly to 45% and 37%, compare to the earlier times points. Overall, Manuka
treatment resulted in a decrease in anti-apoptotic Bcl-2 protein in MDA-MB-231
cancer cells.
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Figure 7. Manuka treatment decreases anti-apoptotic Bcl-2 protein in MDA-MB231. Cells were seeded at 4x10 cells per plate and incubated for 0.25, 0.5, 0.75, 1, 4, 6 and 12 hours
6

in the absence or presence of 1 % (w/v) manuka honey. Whole cell extracts were prepared after
indicated time points. Protein extracts (60µg/lane) were resolved on 10% SDS-PAGE and
immunoblot with Bcl-2-specific monoclonal antibody. The cell extracts were also probed with an
antibody against β-actin as a control for protein loading. The numbers below the blot indicate changes
in band intensity, as determined by densitometric analysis ImageJ. The results are representative of
two independent experiments.
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These findings prompted us to study the impact of Manuka treatment on the
expression of cytochrome c, a pro-apoptotic mediator. As illustrated in Figure 8, the
immunoblot analysis shows a time and concentration dependent increase in the total
protein expression of cytochrome c following Manuka treatment. Remarkably, the
1% Manuka treatment did not induce significant release of cytochrome c at all time
points (from 6 to 48 hours). However, incubation of MDA-MB-231 cells with 5%
Manuka honey induced a marked increase in cytoplasmic cytochrome c levels (202%
of untreated control at 6 hours). This trend continued with increasing times of
incubation reaching 298%, 361%, and 283% of control at 12, 24, and 48 hours,
respectively.

Manuka honey incubation time (Hr):

6
1%

C

1
1% 2

5%

5%

2
4
1%

5%

4
1%8

Mol.weight
(KDa)
5%

Cyto-c

15
1.00

1.29

2.02

1.78

2.98

2.04

3.61

1.32

2.83

45

β−actin

Figure 8. Manuka treatment increases the total protein expression level of
cytochrome c in MDA-MB-231. A. Cells were seeded at 4x10 cells per plate and incubated
6

for 6, 12, 24 and 48 hours in the absence or presence of 1 % and 5% (w/v) Manuka honey. Whole
cell extracts were prepared after indicated time points. Protein extracts (80µg/lane) were resolved
on 10% SDS-PAGE and immunoblotted with cytochrome c specific monoclonal antibody capable
of detecting cytochrome c protein. Cell extracts were also probed with an antibody against β-actin
as a control for protein loading. The numbers below the cytochrome c blot indicate changes in band
intensity, as determined by densitometric analysis ImageJ. The results are representative of two
independent experiments.
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4.3 Effect of Manuka treatment on STAT3 signaling pathway

We next examined how Manuka honey treatment lead to the loss of viability
in cancer cells. Of particular interest is identification of the earliest molecular targets
of Manuka honey in the triple negative MDA-MB-231 human breast cancer cell line.
MDA-MB-231 cells are known to express constitutively activated STAT3 [73].
STAT3 is transcription factor that is often observed constitutively phosphorylated on
tyrosine, and thus activated, in numerous human malignant tumors. The constitutive
activation of STAT3 leads to the dysregulation of various signaling pathways
associated with oncogenesis. These pathways play critical roles in cellular
transformation, proliferation and the suppression of apoptosis. Accordingly, we
chose to examine the effect of Manuka honey on STAT3 phosphorylation in MDAMB-231 cells. Two variables were considered in the course of the treatment:
incubation time and Manuka honey concentration. As early as 15 minutes after
incubation with 1% (w/v) Manuka solution, the level of STAT3 tyrosine
phosphorylation was reduced by 54% compared to the levels observed in untreated
cells, Figure 4A. The inhibition of STAT3 phosphorylation persisted for at least 6
hours but returned to normal levels by 12 hours. The degree of inhibition and
duration of phospho-STAT3 were more pronounced in cells treated with 5% Manuka
solution (Fig. 9B, D). Importantly, Manuka treatment had no effect on total STAT3
protein levels at any of the time points examined (Fig. 9A). This rules out any
influence of the treatment on STAT3 gene transcription or translation.
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Figure 9. Manuka treatment reduces the STAT3 Tyrosine phosphorylation in a time and
dose-dependent manner. A. Cells were seeded at 4x10 cells per plate and incubated for 0.25, 0.5,
6

0,75,1,4,6 and 12 hours in the absence or presence of 1 % (A) and 5% (C) (w/v) Manuka honey. Whole
cell extracts were prepared after indicated time points. Protein extracts (60µg/lane) were resolved on 10%
SDS-PAGE and immunoblotted with STAT3-Tyr-specific (A & C) and STAT3 monoclonal antibody
capable of detecting STAT3-Tyr phosphorylated protein and STAT3 total protein. The cell extracts were
also probed with an antibody against β-actin as a control for protein loading. The numbers below the
STAT3 blot indicate changes in band intensity, as determined by densitometric analysis ImageJ. B &D.
Relative density of p-STAT3 Tyr protein expression in 1% (B) and 5% (D) Manuka treatment is
representing of two independent experiments. Asterisks denote statistically significant differences in
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Next, we were interested to investigate whether Manuka honey could inhibit other
targets that are dependent on tyrosine phosphorylation for their activation. Tyrosine
phosphorylation is an important mechanism of signal transduction that regulates
many essential signaling pathways in eukaryotic cells [74]. Therefore, we looked at
the total tyrosine phosphorylation pattern of Manuka-treated cancer cells. As shown
in Figure 5, Manuka treatment of either concentration 1% (Fig. 10A) and 5% (Fig.
10B) did not alter the gross cellular tyrosine phosphorylation pattern.
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Figure 10. Manuka treatment does not alter the gross cellular tyrosine
phosphorylation pattern. A. Cells were seeded at 4x10 cells per plate and incubated for
6

0.25, 0.5, 0,75,1,4,6 and 12 hours in the absence or presence of 1 % (A) and 5% (B) (w/v)
Manuka honey. Whole cell extracts were prepared after indicated time points. Protein extracts
(60µg/lane) were resolved on 10% SDS-PAGE and immunoblotted with P-Tyr-1000 specific
multiMab monoclonal antibody capable of detecting broad range of tyrosine-phosphorylated
proteins and peptides. The results are representative of one independent experiment.
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4.4 Manuka honey inhibits IL-6 production
It is known that constitutive Stat3 phosphorylation in MDA-MB-231 cells
occurs through an autocrine/paracrine loop involving continuous secretion of IL-6
cytokine [62]. IL-6 binds to the IL-6 receptor and induces the homodimerization of
gp130 that, in turn, triggers the JAK/STAT signaling cascade. In order to examine
the effect of Manuka treatment on IL-6 production, cells were co-treated with
Brefeldin A, a protein transport blocker, to keep IL-6 protein inside the cells and
thereby be detected by western blot analysis. Figure 11 demonstrates clearly the
ability of Manuka honey to inhibit the production of IL-6. At 4.5 hours of Manuka
treatment with 1% or 5% concentration, a significant decrease in the total level of IL6 was observed, amounting to 41 % and 17 %, respectively, of the cytokine levels in
untreated control.
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Figure 11. Manuka Treatment inhibits IL-6 production. A. Experimental procedure.
B. Cells were seeded at 4x10 cells per plate and then co-treated with 1 % and 5% (w/v) Manuka
honey and Brefeldin A for 4 hours. Whole cell extracts were prepared after indicated time point.
Protein extracts (80µg/lane) were resolved on 10% SDS-PAGE and immunoblotted with IL-6specific monoclonal antibody capable of detecting IL-6 total protein. Cell extracts were also
probed with an antibody against β-actin as a control for protein loading. The numbers below the
IL-6 blot indicate changes in band intensity, as determined by densitometric analysis ImageJ.
The results are representative of two independent experiments.
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4.5 Heat treatment of Manuka honey abrogates its STAT3 dephosphryation
activity
Next, we investigated the characteristics of the active compound/s in Manuka
honey that cause the dephosphorylation of STAT3. Therefore, we examined the
effect of boiled honey on MDA-MB-231 cells, specifically on Tyr phospho-STAT3
and total STAT3 protein levels. As shown in Figure 12A, there was no alteration in
total STAT3 protein levels following incubation with heat-treated Manuka solution.
Surprisingly, inhibition of pSTAT3 was abrogated after incubation with 1% or 5%
heat-treated Manuka honey. We also examined the effect of heat-treated Manuka
honey on the expression level of Bcl-2. Heat-treated Manuka honey had no effect on
Bcl-2 level regardless of the concentration, in sharp contrast to the >70% inhibition
observed when fresh Manuka honey solution was used (Fig. 12A). In a further
experiment, cell extracts were prepared after treatment with either fresh or heattreated 5% Manuka solution. As demonstrated in Figure 12B, treatment with heattreated Manuka honey for 30 minutes resulted in 92% pSTAT3 Tyr protein
expression level compared to control. On the other hand, the 5% treatment with
normal Manuka honey for 30 minutes resulted in 69% pSTAT3 Tyr protein
expression level compare to the control 100%.
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Figure 12. Heat treatment of Manuka honey losses its inhibitory effect on STAT3
phosphorylation. A&B. Cells were seeded at 4x10 cells per plate and incubated for 30 minutes
6

in the absence or presence of heat-treated 1 % and 5% (w/v) Manuka honey and normal (unheated)
1 % and 5% (w/v) manuka honey. Whole cell extracts were prepared after indicated time points.
Protein extracts (60µg/lane) were resolved on 10% SDS-PAGE and immunoblotted with STAT3,
pSTAT3 Tyr and Bcl-2 specific monoclonal antibody. Cell extracts were also probed with an
antibody against β-actin as a control for protein loading. The numbers below the blot indicate
changes in band intensity, as determined by densitometric analysis ImageJ. The results are
representative of one independent experiment.
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4.6. STAT3 dephosphorylation is not due to the induction of SOCS3
STAT3 activation is controlled by several post-translational mechanisms.
One of these mechanisms is the induction of negative feedback phosphatases,
enzymes that are capable of removing phosphate groups from their substrates.
Therefore, we hypothesized that the loss of STAT3 phosphorylation could be due to
the induction of tyrosine phosphatases. Suppressor of cytokine signaling 3 (SOCS3)
is an inhibitor that acts as a negative feedback loop in the classical STAT3/JAK2
signaling pathway. SOCS3 expression is induced via IL-6 stimulation and functions
as an inhibitor of cytokine receptor phosphorylation by interfering with JAK2 kinase
activity, thereby preventing further downstream signaling pathway activation [75].
Therefore, we investigated the effect of Manuka honey treatment on SOCS3 total
protein level. As shown in Figure 13, SOCS3 protein expression level did not differ
between control and treated groups. At 0.25, 0.5, 0.75, 1 and 4 of Manuka treatment
the expression level of SOCS3 are 109%, 119%, 124%, 84% and 98%, respectively.
However, at 6 and 12 hours post treatment SOCS3 protein level increased to 167%
and 264% respectively, compared to untreated control.
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Figure 13. STAT3 dephosphorylation is not due to SOCS3. Cells were seeded at 4x10

6

cells per plate and incubated for 0.25, 0.5, 0,75,1,4,6 and 12 hours in the absence or presence of 1 %
(w/v) Manuka honey. Whole cell extracts were prepared after indicated time points. Protein extracts
(60µg/lane) were resolved on 10% SDS-PAGE and immunoblotted with SOCS3-specific monoclonal
antibody capable of detecting SOCS3 total protein. Cell extracts were also probed with an antibody
against β-actin as a control for protein loading. The numbers below the SOCS3 blot indicate changes
in band intensity, as determined by densitometric analysis ImageJ. The results are representative of
one independent experiment.
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Furthermore, we examined gene expression levels of SOCS3 and two other proteins
known to regulate STAT3 activity, protein tyrosine phosphatase non-receptor type 2
(PTPN2) and protein inhibitor of activated STAT3 (PIAS3) by qRT-PCR. No
consistent pattern of alterations in the expression of any of the three genes could be
observed (Figure 14). Maximal induction of ~2-fold over non-treated cells was
observed in SOCS3 after 1 hour of treatment with 1% Manuka honey. For PIAS3 and
PTPN2, minimal changes in gene expression were observed throughout the treatment
period.
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Figure 14. Manuka treatment effect PIAS3, SOCS3 and PTPN1 differently. Cells were
seeded 4x10 cells per plate and incubated for 0.25, 0.5, 0,75,1,4,6 and 12 hours in the absence or
presence of 1 % (w/v) Manuka honey. Each treatment group were seeded in duplicates. Then RNA
were isolated and converted to cDNA to be analyzed by quantitative real-time PCR for three genes,
PIAS3, SOCS3 and PTPN1. The results are representative of two independent experiments.
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4.7. Inhibition of oncoprotein c-Myc by Manuka honey treatment
STAT3 targets several transcription factors that can promote cell growth,
proliferation and survival; c-myc gene is one of these targets. The proto-oncogene cmyc encodes two proteins: p64 and p67, which together form the c-Myc transcription
factor that binds to DNA and activates gene expression [79]. Abnormal expression of
c-Myc has been associated with the initiation and progression of many malignances.
Therefore,

we

examined

the

consequences

of

Manuka-mediated

STAT3

dephosphorylation on c-Myc protein expression level. As shown in Figure 15,
Manuka treatment led to a dramatic decrease in c-Myc, protein, to 78%, 61% and
27% at 0.25, 0.5 and 0.75 hours of treatment. However, after 1 and 4 hours post
treatment c-Myc protein level reached to 77% and 85%, resepectivly, then followed
by significant decreased to 12% at 6 hours of treatment. Finaly, at 12 hours of
Manuka treamtment c-Myc proien level recovered to 95%.
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Figure 15. Inhibition of oncoprotein c-Myc p67 by Manuka honey treatment. Cells were
seeded at 4x10 cells per plate and incubated for 0.25, 0.5, 0,75,1,4, 6 and 12 hours in the absence or
presence of 1 % (w/v) Manuka honey. Whole cell extracts were prepared after indicated time points.
Protein extracts (60µg/lane) were resolved on 10% SDS-PAGE and immunoblotted with c-Myc p68specific monoclonal antibody capable of detecting c-Myc p68 total protein. Cell extracts were also probed
with an antibody against β-actin as a control for protein loading. The numbers below the c-Myc blot
indicate changes in band intensity, as determined by densitometric analysis ImageJ. The results are
representative of two independent experiments.
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4.8. Manuka honey reduced NF-kappa-B-P65 activity in MDA-MB-231 cancer
cells
RELA/NFκB/p65 is one of the most important members in the NF-kappa B
family. It has been found that it regulates many genes in tumorigenesis, survival, and
proliferation. Serine phosphorylation at position 536 is an indicator of
RELA/NFκB/p65 activation and nuclear translocation. Since we found that Manuka
honey inhibits significantly the activity of STAT3, we predicted that it might inhibit
NFκB similarly. Therefore, our goal in this experiment is to examine the effect of
Manuka honey treatment on NFκB total protein and its transcriptional activity. As
illustrated in Figure 16, the level of total NFκB did not differ significantly between
the untreated and treated groups. At 0.25, 0.5, 0.75, 1,4 and 6 of Manuka treatment
the expression level of NFκB are 89%, 94%, 96%, 73%, 86% and 76%, respectively.
However, the level of serine phosphorylated NFκB have decreases as early as 15
minutes post-Manuka treatment to 56% compare to the untreated that is considered
100%. Similarly, at 0.5, 0.75 and 1 hour’s post-Manuka honey treatment, the
phospho-NFκB (Ser536) was maintained reduced to 49%, 59% and 50%,
respectively. However, at 4 and 6 hours the protein level starts to recover and
increase to 78% and 145%, respectively.
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Figure 16. Manuka honey decreased nuclear factor NF-kappa-B-P65 activity in MDA-MB231 cancer cells. Cells were seeded at 4x10 cells per plate and incubated for 0.25, 0.5, 0,75,1,4 and 6 hours
6

in the absence or presence of 1 % (w/v) Manuka honey. Whole cell extracts were prepared after indicated time
points. Protein extracts (80µg/lane) were resolved on 10% SDS-PAGE and immunoblotted with NFκΒ and
NFκΒ (Ser536) -specific monoclonal antibody capable of detecting NFκΒ total protein and serine
phosphorylated NFκΒ. The cell extracts were also probed with an antibody against β-actin as a control for
protein loading. The numbers below the blot indicate changes in band intensity, as determined by densitometric
analysis ImageJ. The results are representative of two independent experiments.
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Chapter 5: Discussion
We have previously demonstrated that Manuka honey has the capacity to
inhibit the proliferation of several types of murine and human cancer cell lines in a
time- and dose-dependent manner in mammary carcinoma [72]. Moreover, the antiproliferative effect of manuka honey was mediated, at least in part, by the induction
of the intrinsic pathway of apoptosis [72]. For the current study, we focused on
investigating the molecular effect of Manuka treatment on a human mammary
carcinoma called MDA-MB-231, which is a triple-negative breast cancer (TNBC)
cell line that lacks gene expression of estrogen and progesterone receptors and
Her2/neu. TNBCs are the most aggressive and difficult to treat type of breast
cancers, with high rates of p53 mutations, constitutive activation of the IL-6/STAT3
signaling pathway, and increased resistance to chemotherapy [61].
Constitutively activated STAT3 results in disrupted cell signaling that promotes cell
proliferation and inhibits apoptosis. This activation drives many proto-oncogenic
pathways that promote cellular oncogenesis. STAT3 plays a pivotal role as a central
mediator in many major cell signaling pathways in the human TNBC cell line MDAMB-231, promoting growth and survival. We have hypothesized that Manuka honey
may block the activity of STAT3 and hence its gene transcriptional activity.
Consequently, the multiple signaling pathways regulated by this transcription factor,
including apoptosis, may well be affected by treatment with Manuka honey.
The findings presented herein identify STAT3 as one of the earliest proteins targeted
by Manuka treatment. Inhibition of STAT3 activity by Manuka treatment occurs
through its dephosphorylation at a critical tyrosine residue (Tyr705) that renders
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STAT3 inactive. There is no evidence that Manuka treatment had any effect on the
total STAT3 protein levels, excluding any influence of the treatment on STAT3 gene
transcription. Instead, Manuka treatment appears to principally inhibit the level of
tyrosine phosphorylation of STAT3 and, consequently, its ability to function as a
transcription factor.
To address the proposed hypothesis, MDA-MB-231 cells were exposed to a low
concentration of Manuka honey (1% w/v) that has previously been shown not to
cause any significant cell death. This was done in order to observe any interruption
of cell signaling pathways without interference by any of the cell death pathways.
These studies demonstrated a significant suppression of STAT3 activity that was
observable as early as 15 minutes post-exposure to Manuka honey. The inhibition in
STAT3 tyrosine phosphorylation persisted for at least 6 hours after exposure to 1%
Manuka solution but, importantly, without any affect on total STAT3 protein levels.
Moreover, the degree and the extent of duration of phospho-STAT3 inhibition were
more pronounced in cells exposed to 5% Manuka solution compared to 1% solution.
This suggested that the concentration of the active component(s) present in the
Manuka honey that acted on STAT3 dephosphorylation was important to achieve
longer duration suppression. In addition, the treatment did not affect the total protein
level of STAT3, but rather reduced its activity only through tyrosine
dephosphorylation. Interestingly, the total tyrosine phosphorylation profile in
western blot analysis showed no significant changes upon treatment with either 1%
or 5% Manuka solution, suggesting that Manuka honey could be selectively
inhibiting STAT3 tyrosine phosphorylation.
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Human MDA-MB-231 TNBC cells depend on constitutive STAT3 activity for their
survival through the induction of anti-apoptotic proteins. The inhibition of upstreamactivated tyrosine kinases such as Src and JAK2, known kinases that activates
STAT3, were found to block STAT3 signaling and result in cell growth inhibition
[62]. Conversely, the inhibition of these kinases in cells that do not express
constitutive pSTAT3, had no effect on their cell growth kinetics [76]. Our current
findings demonstrate that exposure of MDA-MB-231 human breast cancer cells to
Manuka honey is accompanied by a significant decrease in the pro-survival proteins
Bcl-2 and increased cytochrome c protein expression level. This may well be linked
to the ability of Manuka honey to suppress STAT3 activity in these cells thereby
inhibiting its function as a transcription factor that upregulates the expression of prosurvival proteins and, hence, promoting cellular resistance to apoptosis.
One of the important target genes for the STAT3 transcription factor is c-Myc, a
major oncogene that drives cell cycle progression and proliferation. In fact, many
studies indicated that persistent STAT3 activity is associated with increased level of
cell cycle regulator proteins, such as cyclin D1 and c-Myc [9, 78]. In one study,
HepG2 cells (human liver hepatocellular carcinoma), pre-transfected with human cmyc and luciferase genes, were used to investigate IL-6-induced gene expression
[79]. The study demonstrated that increased activation of c-myc RNA expression was
due to IL-6/gb130/STAT3 signaling pathway. Since STAT3 is involved in
transmitting signals mediated by IL-6 stimulation, expression of a dominant negative
STAT3 abolished IL-6 mediated c-myc RNA expression. Moreover, a site in the cmyc promoter region, called E2F site, was identified as the binding site for STAT3
[79], confirming the causal link between STAT3 and c-Myc oncogene.
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It is noteworthy that in our system, exposure of MDA-MB-231 cancer cells to
Manuka honey also led to an inhibition of c-Myc protein expression. The inhibition
was maximal at 6 hours post-exposure and followed the reduction in phosphoSTAT3, which was evident as early as 15 minutes after Manuka honey treatment.
Taken together, Manuka honey-induced inhibition of STAT3 transcriptional activity
also resulted in a reduction of c-Myc protein expression, which accounts for the
observed growth suppression in treated MDA-MB-231 cells.
There is a growing body of evidence that suggests that constitutively activated
STAT3 represents an oncogenic signal in various cell types [80]. In the murine 4T1
TNBC cell line, STAT3 knockdown suppressed the cells’ invasiveness in vitro and
blocked their ability to induce mammary breast tumor and to metastasize in
immunocompetent mice [81]. In a separate study, it was demonstrated that rodent
fibroblasts transformed by the src oncogene expressed constitutively active STAT3
and the loss of this activity prevented src from inducing cellular transformation in
fibroblast cell lines [82]. Furthermore, there is evidence that the presence of activated
STAT3 molecule by itself can lead to cellular transformation [65, 83, 84].
Transfection of different cell lines with an engineered, persistently dimerzeable
STAT3 molecule, called Stat3-C, demonstrated the ability of this molecule to induce
constitutive transcriptional signals that were almost equal to those in v-src
transformed cell line [84]. In addition, nude mice injected with 106 Stat3-Ctransfected primary rat fibroblast cells (called 3Y1 cells) developed tumors 2 to 3
weeks post-injection. In sharp contrast, nude mice injected with the 3Y1 parental cell
line did not develop any tumors over 8 weeks of observation period [84]. The prooncogenic capability of STAT3 is thought to be due to its ability to regulate the
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transcription of many critical genes that play important roles in cell cycle
progression, survival, inflammation, angiogenesis, invasion and metastasis [84].
The potential mechanism by which Manuka honey treatment leads to STAT3
dephosphorylation was also investigated in this study. Sustained activation of STAT3
would require (1) an upstream mutant tyrosine kinase that resists dephosphorylation
or (2) continuously activated receptor-tyrosine kinase complexes or (3) a constitutive
ligand stimulation that creates autocrine or paracrine loop activation (Fig.17). The
precise mechanism underlying constitutively active STAT3 depends on the tumor
type as well as the cellular context.
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Figure 2 | Signalling pathways that converge on STATs. STATs are an important point of
convergence for many signalling pathways that are commonly activated in cancer cells. Binding
of growth factors or cytokines to their receptors results in the activation of intrinsic receptortyrosine-kinase activity or of receptor-associated kinases, such as the Janus kinase (JAK) or SRC
tyrosine kinases. These tyrosine kinases subsequently phosphorylate the cytoplasmic tails of the
receptor to provide docking sites for the recruitment of monomeric STATs. Once they have been
recruited, STATs themselves become substrates for tyrosine phosphorylation. Non-receptor
tyrosine kinases, such as the oncoproteins SRC and BCR–ABL (a fusion of the breakpoint-cluster
region (BCR) and Abelson leukaemia (ABL) proteins), can phosphorylate STATs independently of
receptor engagement. Phosphorylated STATs dimerize and translocate to the nucleus, where the
dimers directly regulate gene expression. Whereas STAT activation is tightly regulated in normal
cells, the persistent activation of tyrosine kinases in cancer causes constitutive activation of STATs
— in particular STAT3 and STAT5. This leads to permanent changes in the expression of genes
that control fundamental cellular processes, which are subverted in cancer cells. Dashed arrows
indicate the ‘recycling’ of STAT proteins from the nucleus to the cytoplasm.

Figure 17: Mechanisms of STAT3 signaling. Obtained from: Jove et
al., The STATs of cancer — new molecular targets come of age,
Nature Reviews Cancer 4, 97-105 (2004).

it has been shown that c-MYC expression is downregulated by IFN-γ, which activates STAT169. In addition,
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It was previously established that in MDA-MB-231 cells, the hyperactivated STAT3
phosphorylation is maintained through IL-6-mediated gp130 cytokine receptortyrosine kinase complex signaling. It has been demonstrated that the inhibition of the
tyrosine kinases Src or the epidermal growth factor receptor, had no effect on STAT3
tyrosine phosphorylation level in MDA-MB-231 breast cancer cells. However,
inhibition of Jak2 or the gp130 cytokine receptor resulted in suppressed STAT3
tyrosine phosphorylation in these cells. In addition, IL-6 sequestration also resulted
in decreased level of STAT3 activity, confirming the critical role of autocrine
signaling through the IL-6/gp130/JAK2/STAT3 pathway in maintaining STAT3 in a
functionally activated state [62].
Accordingly, we investigated the effect of Manuka treatment on IL-6 production by
MDA-MB-231 cells. Our findings confirmed that exposure of cancer cells to
Manuka honey resulted in a dramatic decrease in IL-6 production. The degree of
inhibition in IL-6 production was dependent on the final concentration of manuka
honey used in the treatment, with ~59% and 83% inhibition being observed with 1%
and 5% (w/v) Manuka honey, respectively. Since autocrine stimulation by IL-6 is the
main factor in maintaining STAT3 activation in MDA-MB-231 human breast cancer
cells, Manuka treatment appears to block the autocrine IL-6/STAT3 positive
feedback loop.
Further investigation is needed to clarify if treatment with Manuka honey also
suppresses JAK2 tyrosine kinase activity or reduces the expression level of IL-6
cytokine receptor on MDA-MB-231 cancer cells. Nevertheless, our findings to date
allow us to present a simplified diagram to illustrate the molecular targets of Manuka
honey (See Figure 18).
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Figure 18: Diagram of Manuka honey molecular targets

It is known that the activity of STAT3 is regulated at the post-translational level by
tyrosine kinases and phosphatases as well as by inhibitors [75]. Among the inhibitor
known to act on the STAT3 signaling pathway are SOCS3 and PIAS3 [85]. Like
STAT3, the SOCS-3 inhibitor is also induced by IL-6 family cytokines and binds
directly to the kinase region of JAK2 blocking its interaction with, and hence the
phosphorylation of, gp130 cytokine receptor [86]. In contrast, PIAS3 has been
shown to bind to STAT3 dimers in the nucleus and prevent their binding to DNA,
thereby blocking STAT3 target gene transcription [87]. It is known that PIAS3 is
also subject to cytokine-dependent activation and appears to be a specific inhibitor of
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STAT3 without any effect on other STAT proteins [85]. On the other hand, PTPN1
has the ability to translocate to the nucleus and dephosphorylate activated STAT3
dimer [74]. Therefore, it was important to determine whether Manuka treatment had
any effect of the expression levels of these STAT3 regulators. Our findings
demonstrate that exposure to Manuka honey does not alter mRNA or protein
expression levels of SOCS3, PTPN1 or PIAS3 in MDA-MB-231 cells. These results
suggest that the observed Manuka honey-mediated inhibition of STAT3 is
independent of all of the above regulatory proteins. In a recent study, the effect of
flavone, a plant flavonoid, on STAT3 activity was investigated in human vascular
endothelial cells that lack SOCS3 gene expression [88]. The findings of this study
showed that flavone was able to reduce STAT3 tyrosine phosphorylation despite the
absence of SOCS3, confirming that STAT3 regulation can occur independently of
SOCS3 [88]. It is noteworthy that, in this study, human vascular endothelial cells
were also shown to produce IL-6, which was responsible for maintaining STAT3
hyperactivity in these cells. Similar to our findings with Manuka honey, flavone was
able to interrupt cytokine-induced STAT3 activation [88]. We conclude that Manuka
honey blocks the production of IL-6 and interrupts STAT3 tyrosine phosphorylation
in human breast cancer cells.
Next, we were interested to characterize the chemistry of the active components in
Manuka honey responsible for STAT3 dephosphorylation. We decided to study the
effect of temperature on Manuka honey’s ability to inhibit the expression of STAT3
and pro-survival protein Bcl-2. Our findings demonstrated that heating of Manuka
honey solution(1% or 5% w/v) neutralized the active Manuka honey component(s)
responsible for STAT3 dephosphorylation. Likewise, there was no reduction in the
level of Bcl-2 following exposure of MDA-MB-231 cells to heat-treated Manuka
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honey, suggesting that the active component(s) responsible for the observed cellular
inhibition is heat-sensitive. A previous study reported the capacity of Manuka honey
to induce pro-inflammatory cytokine production by human monocytic cells [57].
This activity was also abolished upon boiling of the unfractionated Manuka honey
solution, suggesting that the active component(s) responsible for this induction is
also heat sensitive [57]. The precise components of Manuka honey that mediate these
various effects on cancer cells and monocytes remain unknown.
In a recent review, the effect of temperature on phytochemicals was reported to have
two contrasting consequences: 1) heat-induced degradation, thus decreased
concentration, of phytochemicals or 2) increase in the extractability of
phytochemicals [89]. The outcome is dependent on the structure of the food matrix
and chemical nature of the specific compound [89]. It has been demonstrated that
temperature in the range of 90°C to 150°C results in reduced antioxidant activity of 8
different phenolic acids, and a linear relationship was found between increasing
temperature and the antioxidant activity [90]. For example, a study investigated the
effect of different cooking techniques on quercetin, one of the flavonoids, content in
onions and tomatoes and found that a loss of 75-80% in quercetin concentration was
evident after boiling for 15 minutes [91]. According to Ayurveda, holistic healing
system developed in India a thousand years ago, heating the honey leads to a loss in
its nutraceutical (nutritional and pharmaceutical) properties [92]. Furthermore,
enzymes present in the honey such as invertase and diastase begin to lose their
activity after 55°C heating treatment [93], and after 100°C total enzymatic
inactivation has been reported [94]. Taken together, the findings of all the above
studies confirm the deleterious effect of heat treatment on phytochemical content and
enzymes present in food.
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IL-6/gp130/JAK2/STAT3

signaling

is

a

crucial

pathway

that

regulates

tumorigenesis, survival, chemotherapy resistance, immune invasion and metastasis
[63, 69, 95]. Each component of this pathway has been targeted and proven its
effectivity against a wide range of cancers [67]. The presence of IL-6 and STAT3
were significantly correlated with high-grade breast cancer that was resistant to
chemotherapy and considered to have poor prognosis [73]. The involvement of IL-6
in cancer progression and invasion has been found in every type of cancer (see Table
2), underscoring the importance of IL-6 as a therapeutic target. More importantly, all
of these studies confirmed the presence of STAT3 that converge the signals from IL6 stimulation.
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Table 2: IL-6 and cancer
Type of cancer

Effect of IL-6

Breast

Regulate VEGF expression and
promoting tumor growth and
metastasis

[96, 97]

Glioma

Promote malignant formation
and progression and induce
VEGF transcription

[98, 99]

Chronic Lymphocytic
Leukemia
Lung
Lymphoma

Worse median survival and
treatment outcome
Increase cell proliferation
Adverse disease outcome, poor
survival and its inhibition
reduced lymphoma growth
Elevated tumor burden and
failure to response to biochemotherapy
Stimulate cell proliferation
Promote inflammatory cytokine
production, angiogenesis and
immune invasion

Melanoma

Multiple Myeloma
Ovarian

Reference(s)

[100]
[101]
[102, 103]

[104]

[105]
[106]

140
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phosphorylated STAT3 is not due to mutations in STAT3 but arises from
oversupply of growth factors, such as TGFα or (IL6-family) cytokines
within the tumor microenvironment that activate STAT3 in a paracrine
manner. The activation of oncogenes, inactivation of tumor-suppressor
genes, chromosomal rearrangement/ampliﬁcation, deregulation of
multiple potential upstream inputs such as elevated EGFR expression
levels, EGFR mutations that result in constitutive RTK activation, overexpression of Src or other SFKs, mutations that hyperactivate JAKs
[89] and other genetic events in neoplastic cells directly trigger
STAT3 activation or the release of inﬂammatory mediators as part
of an autocrine pathway [127]. Hyper-activation of STAT3 can also
result from impairment mutations in any of the negative regulatory
proteins, which limit the extent of STAT3 activation in normal cells
[128]. For example, epigenetic silencing of SOCS3 by hypermethylation
in CpG islands of the functional SOCS-3 promoter in human lung cancers [129] as well as mutations in STAT3-inactivating receptor protein
tyrosine phosphatase delta in glioblastoma and other human cancers
[130] leads to STAT3-mediated cell proliferation and survival.
Forced expression of a constitutively active form of STAT3 in mouse
epidermis was found to shorten latency and enhance the number of
malignant skin lesions progressing rapidly to squamous-cell carcinoma,
induced by two-stage carcinogenesis [131]. Transfection of a dominantnegative form of STAT3 led to production of soluble factors that induce
apoptosis and cell cycle arrest in the murine melanoma model [132].
A growth promoting role for STAT3 in the mouse model of anaplastic
large cell lymphomas mediated by the oncogenic fusion protein,
nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), was demonstrated in both in vitro and in vivo models. Even though NPM-ALKdependent tumor could develop in the absence of STAT3, STAT3 is required for the growth and survival of NPM-ALK lymphoma T cells
in vitro and in vivo. Ablation of STAT3 in mice bearing xenografted
NPM-ALK-dependent T-cell lymphomas signiﬁcantly impaired tumor
growth in vivo [133], suggesting that tumor cells formed in the presence
of STAT3 become STAT3 addicted. Moreover the growth of murine B16
melanoma cells that harbored activated STAT3 could be suppressed efﬁciently in mice by introduction of a functionally deﬁcient STAT3 variant [134]. Constitutive activation of STAT3 is involved in many cellular

processes including proliferation, survival, inﬂammation, invasion,
metastasis and angiogenesis, all of which favor tumor initiation and
progression (Fig. 2) and have been discussed below in detail.
3.1. Proliferation
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Several factors contributed to the emergence STAT
of STAT3
a been
promising
forroles in cell
proteins as
have
shown tomolecule
play important
proliferation induced by cytokines. The ﬁrst evidence towards the
role of STAT3 in survival was that STAT3 activation is essential for
gp130-induced proliferation of the IL-3-dependent pro-B hematopoietic cell line, BAF/B03 cells [135]. In breast carcinoma cells, autocrinemediated STAT3 activation was found to correlate with cell proliferation
[136]. Activated STAT3 promotes proliferation primarily by stimulating
transcription of key cancer genes linked with proliferation of tumor
cells, such as cyclin D1, cyclin B and cdc2, which are involved in the regulation of cell cycle [127]. The active form of STAT3 was found to promote the G1/S phase transition of the cell cycle through the
expression of cyclin D1, which can associate with cdk4 or cdk6 and control progression from G1 to S phase in gastric [137] and colorectal [138]
cancer cells. STAT3 was found to be phosphorylated in 19% of bladder
cancer tissues as well as several bladder cancer cell lines. Targeting
the STAT3 signaling pathway in bladder cancer cells using an
adenovirus-mediated dominant-negative STAT3 prohibited cell growth
and induction of apoptosis in bladder cancer cell lines through downregulation of cell cycle-regulating gene cyclin D1 [139]. In human
head and neck squamous cell carcinoma, constitutive activation of
STAT3 was found to play a causative role in over-expression of cyclin
D1, and in clinical studies, STAT3 activation level provided a novel prognostic factor [140]. Cucurbitacin I-mediated inhibition of STAT3induced cell-cycle arrest at the G2/M transition in cell lines derived
from laryngeal squamous cell carcinoma and glioblastoma was associated with the downregulation of cyclin B1 and cdc2 [138]. Constitutively
phosphorylated STAT3 has been found to induce over-expression of target genes such as cdc2, cyclin B1, m-ras, and E2F-1 in colon and breast
carcinomas. E2F-1 is a transcription factor that activates the synthesis
of mRNAs encoding proteins needed during the cell cycle. The products
of some E2F-1-regulated genes, such as cyclin D1 and cyclin E, cdc2 and

therapeutic intervention. Firstly, its acts as a central converge of three main signaling

pathways known to enhance oncogenesis: Src non-receptor tyrosine kinase,
epidermal growth factor receptor and IL-6/cytokine receptor. Secondly, the activity

of STAT3 regulates a wide range of genes that affect cancer at multiple levels, such

as malignant progression, invasion, angiogenesis, survival, chemotherapy resistance

and immune evasion (see Fig.19) [65]. Thirdly, studies done in normal mouse
fibroblasts have showed that suppressing STAT3 signaling is not lethal in normal
cells growth, because normal cells are not totally dependent on STAT3 signaling and

are capable to use another signaling pathways to overcome the absence of STAT3
[83, 107].

Fig. 2. Multifaceted role of STAT3 in tumor invasion and metastasis.

Figure 19: STAT3 target genes. obtained from: Bishayee et al.,
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and
natural inhibitors, Biochimica et Biophysica Acta 1845,136–154p,
(2014).
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In summary, many studies have provided further evidence to the importance of
STAT3 as a therapeutic target. Our current findings demonstrate that Manuka honey
has the ability to inhibit the autocrine/paracrine feedback loop of IL-6/STAT3
signaling pathway in human breast cancer cells leading to growth arrest and loss in
viability. This cellular target is crucial since it plays critical roles in malignant
progression, invasion, angiogenesis, survival, chemotherapy resistance and immune
evasion. Inactivation of STAT3 leads to a loss in its transcriptional activity and,
consequently, loss in the expression of many of the genes under STAT3
transcriptional regulation.
Finally, additional studies are needed to delineate exactly how Manuka honey
achieves this effect. Possible mechanisms include the direct inhibition of the JAK2
tyrosine kinase activity, prevention of ligand binding to IL-6 receptor or through
inducing the degradation of the cytokine receptor. Additionally, further analysis is
needed to investigate in depth the characteristics of the active compounds in Manuka
honey and compare them directly with known purified phytochemicals.
In conclusion, our findings identified IL-6/STAT3 signaling pathway as an early
target of the anti-tumor activity of Manuka honey in human breast cancer cells.
Given the demonstrated importance of this pathway in regulating the growth of
different types of human tumors, Manuka honey may exert similar inhibitory effects
on a range of cancers.
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